These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24505199)

  • 41. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
    Jonas JB; Tao Y; Rensch F
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
    Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
    Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration.
    Yoshizawa C; Saito W; Hirose S; Kitamei H; Noda K; Ishida S
    Jpn J Ophthalmol; 2013 Jan; 57(1):68-73. PubMed ID: 23093314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
    Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study.
    Giansanti F; Virgili G; Bini A; Rapizzi E; Giacomelli G; Donati MC; Verdina T; Menchini U
    Eur J Ophthalmol; 2007; 17(2):230-7. PubMed ID: 17415697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
    JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration.
    Selid PD; Jundt MC; Fortney AC; Beal JR
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(4):275-81. PubMed ID: 25037009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
    Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
    Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M
    Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
    Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
    Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
    Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
    Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema.
    Yu SY; Nam DH; Lee DY
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):39-47. PubMed ID: 29030692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fundus autofluorescence not predictive of treatment response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Chhablani J; Kozak IR; Mojana F; Cheng L; Morrison VL; Wang H; Kim JS; Dustin L; Azen S; Freeman WR
    Retina; 2012 Sep; 32(8):1465-70. PubMed ID: 22466489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.